18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Slides:

Advertisements

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Volume 24, Issue 5, Pages (November 2013)

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

BV6 increases tumor burden in bone.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Volume 18, Issue 3, Pages (January 2017)

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

The therapeutic effects of HDAC and mTOR inhibitors are mediated by the suppression of class I HDACs and require oxidative stress. The therapeutic effects.

Fig. 3. TKI sensitivity assessed by the MANO method.

by Nicholas J. Laping, Michael P. DeMartino, Joshua E

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 dosing on long-term efficacy.

Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in vitro and in vivo. Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in.

NCMs regulate T cell survival in TLOs via PD-L1.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Plasma and tissue EGFR allele analyses.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

HMQ1611 inhibited breast tumor growth in mice.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Change in FES uptake in the tumor during fulvestrant treatment.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

A, transversal and coronal microPET images of 89Zr-ranibizumab at 24 hours pi of the tracer. A, transversal and coronal microPET images of 89Zr-ranibizumab.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

PDL192 and inhibit the growth of xenograft tumors.

Effects of ZOL treatment on pulmonary metastases.

GCS-100 selectively kills KRAS-addicted lung tumors.

VEGF-A inhibition impedes proliferation in Amppos tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Curative effect of W+T treatment in vivo.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

Dose-dependent effect of IP6 feeding on angiogenesis in prostate of TRAMP mice. Dose-dependent effect of IP6 feeding on angiogenesis in prostate of TRAMP.

Fig. 3 MCA-mediated neutrophil recruitment accelerates bacterial clearance in the skin. MCA-mediated neutrophil recruitment accelerates bacterial clearance.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Presentation transcript:

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. A, representative images of FDG–PET scans of animals treated with vehicle, PD-0325901, rapamycin, or both (Rap–PD). PD-0325901 was dosed twice daily. Baseline scans are shown at left (pre-), and the right image shows the same view of the same animal 40 hours after treatment with the indicated compound (post-). Arrow, MPNST. Scale bar, relative 18F-FDG uptake, with low uptake in blue and highest uptake in white. B, the 18F-FDG uptake by tumors was quantified using SUVmax, and the log2 of the fold change of this number was calculated to indicate the change in 18F-FDG uptake 40 hours after treatment relative to baseline for each animal. The change in combination-treated animals (Rap–PD) is compared with monotherapy and vehicle-treated animals (controls). The y-axis indicates the log2 of the fold change in SUVmax relative to baseline. C, representative images of FDG–PET scans of animals treated with 100% PD-0324901–rapamycin, 50%PD-0325901–rapamycin, or 25% PD-0325901–rapamycin. The left image (pre-) shows the baseline scan for each animal and the right (post-) shows the scan 40 hours after treatment with the indicated dose. Again, the tumors are indicated with arrows. Scale bar, relative FDG uptake, with low uptake in blue and highest uptake in white. D, left, a waterfall plot depicting the log2 fold change of SUVmax, a quantification of tumor FDG–PET activity, of selected tumors at 40 hours after treatment with PD-0325901 (25%, 50%, or 100% of the dose) and rapamycin. Right, a waterfall plot depicting the log2 of fold change in tumor volume of the same mice after 10 days. Individual tumors are graphed in the same order on each plot. E, regression analysis of nine combination-treated mice (100%, n = 3; 50%, n = 3; 25%, n = 3). The x-axis represents the log2 of fold change in tumor volume at 10 days, and the y-axis represents the log2 of fold change in SUVmax levels after 40 hours of treatment. Both numbers are relative to day 0 measurements. Line, best-fit linear correlation, and the Pearson coefficient (r) was calculated. Clare F. Malone et al. Cancer Discovery 2014;4:1062-1073 ©2014 by American Association for Cancer Research